🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Claritev Corporation CTEV R2K

Healthcare · Health Information Services · United States
https://www.claritev.com

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.

READ MORE ›
$25.12
-34.67% 1Y

Market & Price

Market Cap
$428.24M
Current Price
$25.12
High / Low (52W)
$72.58 / $13.47
Beta
0.77

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
3.67
PEG Ratio
-
Book Value
$-14.18
Price to Book
-1.77
P/S
0.44
EV/EBITDA
9.66
Dividend Yield
-

Profitability & Returns

ROCE
0.41%
ROE
-
ROA
1.10%
Profit Margin
-29.27%
Op Margin
7.55%
EPS (Latest Qtr)
$-4.41
EPS (TTM)
$-17.33

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.93
Current Ratio
1.28
Debt
$4.74B
Total Assets
$4.89B
Current Assets
$224.37M
Working Capital
$-36.99M

Ownership

Promoter Holding
7.44%
Chg in Prom Hold
-
FII / Inst Holding
90.93%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$5.15B
Total Revenue (TTM)
$978.76M
EBITDA
$533.34M
Free Cash Flow
$108.93M
Operating Cash Flow
$101.60M
Shares Outstanding
17.05M
Gross Margin
73.23%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-3.66%
Profit 5Y
16.79%
Revenue (YoY)
5.80%
Earnings (YoY)
-

PROS

  • Profit CAGR of 16.8% over 5 years.
  • Generates positive free cash flow.

CONS

  • Revenue declined at -3.7% CAGR over 5 years.
  • Trading 65.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CTEV Claritev Corporation R2K 25.12 - $428.24M - 0.41% - -3.66% 16.79%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 245.02M245.65M245.82M246.40M252.02M206.88M223.52M255.34M254.86M276.27M288.21M298.05M290.13M250.45M236.59M237.99M242.80M234.51M233.48M--231.33M241.57M245.96M246.55M244.68M
Cost of Revenue ---------------------77.20M79.13M82.31M78.03M80.81M
Gross Profit ---------------------154.13M162.44M163.65M168.52M163.87M
Operating Expenses ---------------------140.72M145.86M153.59M159.85M157.19M
Operating Income 85.10M99.32M81.11M102.68M87.62M20.27M-199.50M-40.20M82.27M89.80M104.45M116.64M97.77M36.40M46.94M34.71M39.52M-486.44M-523.93M--13.41M16.58M10.07M8.67M6.68M
EBITDA ---------------------113.31M128.83M120.49M104.77M118.47M
Interest Expense ---------------------91.64M99.75M101.23M99.41M99.54M
Pretax Income ----------------------89.87M-82.93M-93.36M-106.92M-92.72M
Tax Provision ----------------------18.55M-20.29M-23.61M-26.35M-19.16M
Net Income -8.36M868.00K5.36M11.84M-2.59M-56.25M-288.40M-173.32M45.88M-46.93M78.20M43.98M13.51M19.74M209.00K-36.37M-24.14M-539.69M-576.73M---71.32M-62.64M-69.75M-80.57M-73.56M
Diluted EPS -----0.01-0.14-0.69-0.07-0.070.120.070.020.030.00-0.06-1.49-33.40-35.78---4.38-3.81-4.23-4.88-4.41

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.04B982.90M937.76M1.12B1.08B961.52M930.62M965.41M
Cost of Revenue ----204.10M295.62M303.45M316.37M
Gross Profit ----875.62M665.90M627.17M649.05M
Operating Expenses ----541.44M494.98M518.92M603.99M
Operating Income 427.54M368.21M-131.82M386.12M334.18M170.92M108.26M45.06M
EBITDA ----158.32M651.93M-1.01B467.40M
Interest Expense ----303.40M333.21M326.37M392.02M
Pretax Income -----560.74M-107.06M-1.77B-373.08M
Tax Provision ----12.17M-15.36M-124.88M-88.80M
Net Income 36.22M9.71M-520.56M102.08M-572.91M-91.70M-1.65B-284.28M
Diluted EPS -0.02-1.110.16-36.00-5.69-101.92-17.30

Compounded Sales Growth

5 Years:-3.66%
1 Year:5.80%

Compounded Profit Growth

5 Years:16.79%
1 Year:-

Stock Price Performance

1 Year:-34.67%
6 Months:-51.89%
3 Months:+86.49%
1 Month:+8.93%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --8.36B8.28B-7.37B6.96B5.15B4.89B
Current Assets -----446.74M193.59M175.51M224.37M
Cash & Equivalents --21.82M126.75M-334.05M71.55M16.85M16.81M
Inventory ---------
Receivables -----78.91M76.56M89.76M127.61M
Total Liabilities --6.38B5.73B-5.58B5.26B5.07B5.06B
Current Liabilities --85.79M112.50M-175.84M166.74M213.79M261.36M
Long Term Debt -----4.74B4.53B4.51B4.58B
Total Debt -----4.78B4.57B4.54B4.62B
Total Equity 1.95B1.99B1.99B2.56B-1.79B1.71B84.02M-173.90M
Shares Outstanding -----16.66M16.70M16.93M17.30M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 292.30M284.31M377.37M-372.36M171.72M107.62M117.32M
Investing Cash Flow -63.56M-66.41M-210.84M--104.45M-249.79M-118.12M-121.02M
Financing Cash Flow -245.15M-201.09M-61.60M--115.74M-180.99M-41.31M2.36M
Capital Expenditure -63.56M-66.41M-70.81M--89.73M-108.85M-118.12M-129.60M
Free Cash Flow 228.75M217.90M306.56M-282.63M62.87M-10.51M-12.28M
Net Change in Cash ----152.18M-259.06M-51.82M-1.33M
Share Buybacks 00101.12M100.00M015.22M10.37M0

Ratios (Annual)

Figures in %.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----81.1%69.3%67.4%67.2%
Operating Margin % 41.1%37.5%-14.1%34.5%31.0%17.8%11.6%4.7%
Net Margin % 3.5%1.0%-55.5%9.1%-53.1%-9.5%-176.9%-29.4%
ROE % 1.8%0.5%-20.4%--32.0%-5.4%-1,958.8%163.5%
ROCE % -4.4%-1.6%-4.6%2.5%2.2%1.0%

Shareholding Pattern

Insiders
7.44%
Institutions
90.93%
Public Float
98.24%

Top Institutional Holders

#Holder% HeldSharesValue
1 H&F Corporate Investors VIII, Ltd. 22.81% 3.89M $97.66M
2 Ares Management LLC 10.93% 1.86M $46.80M
3 Arini Captial Management Ltd 9.00% 1.53M $38.55M
4 Public Investment Fund 7.52% 1.28M $32.19M
5 Beach Point Capital Management LP 4.67% 795.35K $19.98M
6 Blackrock Inc. 3.45% 588.00K $14.77M
7 CPV Partners, LLC 2.91% 495.26K $12.44M
8 Vanguard Capital Management LLC 2.52% 430.07K $10.80M
9 CASPIAN CAPITAL, LP 2.09% 356.25K $8.95M
10 Prudential Financial, Inc. 2.08% 353.74K $8.89M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CTEV

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks